New symmetrical acyclic and alicyclic bisurea derivatives of 4,4'-methylenebis(phenyl isocyanate): Synthesis, characterization, bioactivity and antioxidant activity evaluation and molecular docking studies

Naga Raju Chamarthi1*, Venkata Chalapathi Ponne2*, Hari Babu Pulluru2,3, Janakiramudu Dasari Balija2,3, Sindhu Reddy Gutala4, Saritha Venkatareddy Kallimakula4, Venkataramaiaah Chintha5 and Rajendra Wudayagiri5

1Department of Chemistry, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India
2Department of Chemistry, Sri Venkateswara Arts College (TTD’s), Tirupati, 517502, Andhra Pradesh, India
3Department of Chemistry, P. V. K. N. Government College, Chittoor, 517002, Andhra Pradesh, India
4Department of Future Studies/Biotechnology, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India
5Division of Molecular Biology, Department of Zoology, Sri Venkateswara University, Tirupati, 517502, Andhra Pradesh, India

(Received March 11, 2018; Revised April 24, 2018; Accepted April 29, 2018)

Abstract: A family of bisurea derivatives of 4,4'-methylenebis(phenyl isocyanate) have been synthesized with simple, effective and efficient procedure in high yields. The new compounds showed moderate bioactivity (at 32.0 µg/µL concentration) against selected bacterial pathogens, viz., Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa; and two fungal species, Candida albicans and Cryptococcus neoformans var. grubii. Alternatively, their antioxidant activity was also evaluated by DPPH radical scavenging assay which revealed that the compounds, 10d, 10e, 10h and 10m exhibited moderate activity. However, the molecular docking studies of all the title compounds showed surprisingly higher binding energies with DNA gyrase A protein of E. coli when compared to the reference, streptomycin. Among the compounds 10e, 10f, 10g, 10k, 10l and 10m showed very good binding energies which implied that they could be promising next generation antimicrobials.

Keywords: 4,4'-Methylenebis(phenyl isocyanate); antimicrobial activity; antioxidant activity; molecular docking. ©2018 ACG Publication. All right reserved.

1. Introduction

The doom and gloom of antibiotic resistance dominates public perception of drugs for chemotherapy. The 2014 Report of WHO on global surveillance of antimicrobial resistance revealed
that “antibiotic resistance is no longer a prediction for the future; it is happening right now, across the world, and is putting at risk the ability to treat common infections in the community and hospitals”.

Because of the marshaling of resistome (the accumulation of antibiotic-resistant genomes anchored in environmental bacterial populations and bacterial pathogens) genes into professional as well as opportunistic infectious agents there is always a necessity for the next generation of antimicrobial agents. The root of vancomycin resistance, for example, originate from the shipment of vanHAX genes from constitutionally resistant soil microbes such as Lactobacilli and Leuconostoc strains to Enterococci where they dwell on transposable elements.

The morbific microbes especially “ESKAPE” pathogens, Enterococcus faecium, Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE) (Gram-positive); Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacter species (Gram-negative) set a clinical challenge and become a threat to the survival of man on this planet. Man cannot be the ultimate species of appreciation unless he undermines these invisible conquerors of the world. To sustain mankind on earth one must be cautious of i. the existence of superbugs ii. the spreading of resistance world-wide iii. the tie-up of death and resistance and iv. the need to design and develop novel “magic bullets”.

The fundamental strategy to eradicate the pathogenic agents banks on its kind. The antibiotics can be bactericidal (kill bacteria) or bacteriostatic (stop bacteria from multiplying) based on their mode of action. The antibiotics can also be of narrow-spectrum (effective against only a few types of bacteria) or broad-spectrum (effective against a wide range of bacteria inclusive of Gram-positive and Gram-negative bacteria) based on their bioactivity over the range of pathogens. Gram-positive infections are treated with drugs that i. inhibit the topoisomerase IV ii. inhibit the folate synthesis iii. inhibit the cell wall synthesis and iv. disrupt the plasma membrane while Gram-negative infections with drugs that i. inhibit the protein synthesis and ii. inhibit the DNA or RNA synthesis.

Antimicrobial agents can be classified as i) antibacterials (synthetic origin), ii) antibiotics (microbial origin), iii) antivirals, iv) antiprotozoals, v) antifungals and vi) antiparasitic drugs. Many of the antivirals, antiprotozoals, antifungals and antiparasitic drugs are of synthetic or semisynthetic origin. The microbial originated antibiotics include penicillins, cephalosporins, macrolides, glycopeptides, tetracyclines, aminoglycosides, etc. The synthetic antibacterials include ansamycins, aminoglycosides, macrolides, tetracyclines, lincosamides, pleuromutilins, streptogramins, sulfonamides, etc. Penicillins, cephalosporins, monobactams, carbapenems find therapeutic value which are on constant drug designing to combat the pathogens of time.

The expedition beyond the frontiers of drugs today ended up with new molecular frameworks. For example, TK-666, a potent synthetic inhibitor of bacterial thymidylate kinase was developed by AstraZenica. Platensimycin, a potent inhibitor of bacterial thymidylate kinase was developed by Merck.

Oxidation can be a chemical reaction that can produce reactive oxygen species (ROS) such as H2O2, HOCl, HOBr, ROOH, HNO2, ozone O3, singlet oxygen O2, free radicals like oxygen radical, O2·-, superoxide radical anion, O2−, hydroxyl radical, ‘OH, perhydroxyl radical, ‘OH, alkoxyl radical, RO·, peroxy radical, ROO·, and reactive nitrogen species (NOS) nitric oxide, NO; Nitrogen dioxide, NO2· and peroxyinitrite radical, ONOO− leading to chain reactions that may damage cellular components such as proteins (enzyme inhibition, denaturation, degradation), lipids (lipid peroxidation) and DNA (mutations, cancer). An antioxidant is a molecule that prevents the oxidation of other molecules. Antioxidants terminate these chain reactions. Antioxidants are used for two different groups of materials: industrial chemicals added to products to prevent oxidation and natural chemicals found in food and body tissues which exert beneficial health benefits as well as redox signaling. It’s a paradox in metabolism that oxygen is required for the existence of life on the Earth and it damages the living cells. When the body fails to balance or counteract or detoxify the harmful effects of free radicals by means of antioxidants oxidative stress results. Oxidative stress leads to many pathophysiological conditions which include neurodegenerative disease such as Alzheimer’s diseases such as Parkinson’s disease, neurodegeneration in motor neuron diseases, the pathologies caused by diabetes, rheumatoid arthritis, gene mutations and cancers, fragile X syndrome, chronic fatigue syndrome, heart and blood vessel disorders, heart attack, heart failure, atherosclerosis and
inflammatory diseases. Many antioxidant enzymes such as catalase, glutathione peroxidase, glutathione reductase, glutathione S-transferase, superoxide dismutase, etc, protect DNA from oxidative stress. It is found that heavy metals like lead induce oxidative stress by i. producing ROS and ii. Depleting cellular antioxidant reserves. Dietary antioxidants, vitamin A, vitamin C, vitamin E and β-carotene, glutathione (mother of antioxidants), flavonoids, catechins, polyphenols, selenium, etc, are found to exert a beneficial health effect if treated with. For treating lead toxicity vitamin C, vitamin E, methionine, N-acetyl cysteine, zinc, selenium, α-lipoic acid, pyridoxine or taurine are combined with chelators such as CaNa<sub>2</sub>EDTA and DMSA.

Figure 1. Bioactive urea/bisurea derivatives

As the virulent pathogen modifies its genetic constitution to evade antibiotic inhibition and acquires defense mechanisms to become resistant to antimicrobials there is always a unique reason to explore new antimicrobials to sustain human race and to avoid miserable ailments due to pathophysiology. The quest for exploring new frontiers of antimicrobials has bloomed emphatically
for the past two decades or so, goaded by brewing threat of microbial resistance. As our armory of “magic bullets” is getting old and less efficient only a few original replacements have become available. A number of reasons, chilling R & D costs, highly competitive market and the inability to identify ingenious antimicrobial targets, have rephrased in to a proliferative occurrence of nosocomial infective agents which no longer responsive to I or II line of antimicrobials. Deteriorating efficacy of therapeutic arbitration extends across all kinds of microbial pathology, weather caused by virus, bacteria, fungi or parasites and new diagnostic tools and therapeutic arms and ammunition are very much needed to decipher this perplexing puzzle.

One such promising niche of antimicrobials and antioxidants is urea derivatives. Urea derivatives have been widely used as anticancer agents; as an anticolorectal cancer agent; cytoxic agents, anti-HIV-1 agents and antimicrobial agents; as Antiepileptic agents; as telomeric and genomic G-quadruplex DNA interacting agents; as superoxide scavenging agents; as hypoglycemic and antibacterial agents; as anthyperyglycaemic agents; as anti-inflammatory and antimicrobial agents; as antiallergic agents; as antiproliferative agents against A375P human melano ma cell lines; as strong and broad-spectrum antiproliferative agents against different cancer types; as cytostatic and antioxidative agents; as anti-TB or antimiycobacterial agents; and as antibacterial agents as antimicrobial agents.

Regorafenib, (2) a urea derivative and a broad-spectrum kinase inhibitor targeting the RAS/RAF/MEK/ERK pathway has been approved by FDA to treat metastatic colorectal cancer (CRC) and gastrointestinal stromal tumors.

Yet bisurea derivatives also proved to be as biological potential of hybrid molecules with anti-fungal, anti-TB, anti-malarial, anti-inflammatory and anti-cancer activities. They have also been HIV protease inhibitors; cytostatic and antioxidative agents; antiproliferative agents; antileukemia agents; anticonvulsants; Raf kinase inhibitors in human cancer cell lines; antimicrobial agent against E. coli; antibacterial and antioxidative agents and thymidine phosphorylase inhibitors. Amazingly trisurea derivatives induced apoptosis in human cancer cells.

In the light of MDR nature of urea moiety in regorafenib and antibacterial nature of several urea derivatives, as a choice and chance to explore for new niches of anti-infective agents the authors have selected a new simple template molecule, 4,4′-Methylenebis(phenyl isocyanate) and crafted it to meet the need (synthesis of 10a-g & 10h-m) in a simple efficient nucleophilic addition reaction.

2. Materials and Methods

2.1. Chemicals and Apparatus

All the chemicals were purchased from Sigma-Aldrich and Merck and were used as such without further purification. The solvents used for spectroscopic studies and other physical studies were reagent grade and were purified further by literature methods.

The melting points were determined on EZ-Melt Automated Melting Point Apparatus equipped with Digital Imaging Processing Technology of Stanford Research Systems using open capillary method and are uncorrected.

The IR spectra were recorded on a Bruker Alpha-Eco ATR-FTIR (Attenuated Total Reflection – Fourier Transform Infrared) Interferometer with single reflectionsampling module equipped with ZnSe Crystal and reported in reciprocal centimeters (cm⁻¹).

1H and 13C NMR spectra were recorded in DMSO-d₆ solvent on a Bruker FT-NMR 400 MHz spectrometer operating at 400 MHz for 1H NMR and 100 MHz for 13C NMR. The 1H and 13C NMR chemical shifts were referenced to tetramethyl silane and reported in delta, δ values in ppm. Multiplicities were abbreviated as s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), m (multiplet) and br s (broad singlet).

The mass spectra were recorded on LCMS-2010A Shimadzu mass spectrometer equipped with electron spray ionization (ESI) source at atmospheric pressure in positive ion mode. A 10⁻³ M solution of 10a and 10m were prepared in HPLC grade DMSO separately. Each solution was infused in to the mass spectrometer at a rate of 6 μL/min. The optimized conditions set for ESI were as shown: dry N₂ flow rate 12 L/min. at 200 °C; the nebulizer N₂ was operated at 35 psi; capillary voltage was 4000 V; the skimmer was at 65 V; and the fragmenter was maintained at a voltage of 90 V. Quantification was performed in selected ion monitoring (SIM) mode using target ions m/z 374 for 10a and m/z 450 for
New symmetrical acyclic and alicyclic bisurea derivatives

10m. The CHN Analysis was carried on Flash EA 1112 Series Thermo Finnigan for 10a and 10m compounds.

2.2. Synthesis of Acyclic and Ayclic bisurea derivatives of 4,4'-Methylenebis(phenyl isocyanate)

To a mixture of 4,4'-methylenedibis(phenyl isocyanate) (8) (0.001 mol, 0.250 g) and 0.6 mL of triethyl amine (TEA) in THF (10 mL) contained in a 50 mL RB flask, 2-aminoethanol (9a) (0.002 mol, 0.122 g, 0.12 mL) was added drop-wise at 10-15 °C with constant stirring. Later the reaction mixture was stirred at 45-50 °C for 1 hr. The progress of the reaction was monitored by TLC. The product, 10a was filtered off as it was insoluble in THF and washed with a little methanol to get pure compound in excellent yield. The compounds were further purified using column chromatography. The same procedure was adopted for the synthesis of other title compounds 10b-m using different substituted acyclic amines, 9b-g and alicyclic amines, 9h-m as depicted in Scheme 1.

![Scheme 1. Synthesis of new bisurea derivatives of 4,4'-Methylenebis(phenyl isocyanate).](image)

| Compound | R       | Compound | R       | Compound | R       | Compound | R       |
|----------|---------|----------|---------|----------|---------|----------|---------|
| 9a       | OH      | 9b       | OH      | 9c       | OH      | 9d       | F       |
| 9e       | N       | 9f       | F       | 9g       |         | 9h       |         |
| 9i       |         | 9j       |         | 9k       | N-CH3   | 9l       |         |
| 9m       |         |          |         |          |         |          |         |

2.3. Spectral Data

1,1'-(methylenebis(4,1-phenylene))bis(3-(2-hydroxyethyl)urea) (10a): Pale yellow solid, yield:89%, mp: 167.3 °C; IR (cm⁻¹): 3314 (O-H and N-H str), 3030 (Ar C-H str), 2939 (ali. Methylene C-H str), 2880 (Ar-CH₂-Ar C-H str), 1629 (C=O str), 1571 (C=C str), 1246 (C-N str), 1026 (C-O str), 811 (p-disub. Benzene C-H str); ¹H NMR (400 MHz, DMSO-d₆) δ: 8.69 (2H, s, N-H-7, 7'), 7.27-7.00 (8H, dd,
1,1'-(methylenebis(4,1-phenylene))bis(3-(2-chlorobenzyl)urea) (10f): White solid, yield: 97%, mp: 257.3 °C; IR (cm⁻¹): 3413 (O-H str), 3324 (N-H str), 3043 (Ar C-H str), 2936 (Ali. Methyne C-H str), 2876 (Ar-CH₂-Ar C-H str), 1630 (C=O str), 1560 (C=C str), 1504 (C-N str), 1057 (C-O str), 917 (O-H bend), 813 (p-disub. Benzene C-0, C-0').

1,1'-(4,4'-methylenebis(4,1-phenylene))bis(3-(3-hydroxypropyl)urea) (10b): White solid, yield: 93%, mp: 211.4 °C; IR (cm⁻¹): 3413 (O-H str), 3320 (N-H str), 3041 (Ar C-H str), 2936 (Ali. Methylene C-H str), 2876 (Ar-CH₂-Ar C-H str), 1630 (C=O str), 1560 (C=C str), 1504 (C-N str), 1057 (C-O str), 917 (O-H bend), 813 (p-disub. Benzene C-0, C-0').

1,1'-(4,4'-methylenebis(4,1-phenylene))bis(3-(1-hydroxybutan-2-yl)urea) (10c): Pale yellow solid, yield: 91%, mp: 178.9 °C; IR (cm⁻¹): 3482 (O-H str), 3292 (N-H str), 3076 (Ar C-H str), 2951 (Ali. CH₃ C-H str), 2890 (Ali. Methyne C-H str), 2873 (Ar-CH₂-Ar C-H str), 1627 (C=O str), 1559 (C-C str), 1400 (C-H bend), 1294, 1225 (C-N str), 1047 (C-O str), 822 (p-disub. Benzene C-H str); ¹H NMR (400 MHz, DMSO-d₆) δ: 8.20-7.94 (8H, dd, J = 7.6 Hz, Ar-H-3, 5, 3', 5', 2, 6, 2', 6'), 6.99 (2H, s, N-H-9, 9'), 5.42 (2H, s, O-H-13, 13'), 4.67 (2H, s, benzyllic H-0, 0'), 4.38-4.30 (8H, m, H-12, 12', 10, 10', 10''), 4.06 (4H, t, J = 5.6 Hz, H-11, 11, 11', 11'').

2.3.5. 1,1'-(methylenebis(4,1-phenylene))bis(3-(pyridin-3-ylmethyl)urea) (10e): White solid, yield: 96%, mp: 238.7 °C; IR (cm⁻¹): 3302 (N-H str), 3033 (Ar C-H str), 2960 (Ali. CH₃ C-H str), 2838 (Ar-CH₂-Ar C-H str), 1630 (C=O str), 1563 (C=C str), 1415 (C-H bend), 1303, 1236 (C-N str), 819 (p-disub. Benzene C-H str); ¹H NMR (400 MHz, DMSO-d₆) δ: 8.49 (2H, s, N-H-7, 7'), 7.33-7.05 (8H, dd, J = 8.4 Hz, Ar-H-3, 5, 3', 5', 2, 6, 2', 6'), 6.98 (2H, d, J = 5.2 Hz, Ar-H-15, 15'), 6.96 (2H, t, J = 3.6 Hz, Ar-H-14, 14'), 6.62 (2H, t, J = 6 Hz, N-H-9, 9'), 4.46 (4H, d, J = 5.6 Hz, H-10, 10', 10', 10''), 3.77 (2H, s, benzyllic H-0, 0').

1,1'-(methylenebis(4,1-phenylene))bis(3-(4-fluorobenzyl)urea) (10f): White solid, yield: 97%, mp: 240.7 °C; IR (cm⁻¹): 3320 (N-H str), 3036 (Ar C-H str), 2927 (Ali. CH₂ C-H str), 1620 (C=O str), 1555 (C=C str), 1413 (C-H bend), 1299, 1214 (C-N str), 1099 (C-F str), 821 (p-disub. Benzene C-H str); ¹H NMR (400 MHz, DMSO-d₆) δ: 8.49 (2H, s, N-H-7, 7'), 8.53 (2H, d, J = 1.6 Hz, Ar-H-12, 12'), 8.46-8.44 (2H, dd, J = 1.2 Hz, Ar-H-14, 14'), 7.71 (2H, d, J = 8 Hz, Ar-H-16, 16'), 7.36 (2H, t, J = 4.8 Hz, Ar-H-15, 15'), 7.33-7.04 (8H, dd, J = 8.4 Hz, J = 8.4 Hz, Ar-H-3, 5, 3', 5', 2, 6, 2', 6'), 6.85 (2H, t, J = 6 Hz, N-H-9, 9'), 4.32 (4H, d, J = 6 Hz, H-10, 10'), 3.76 (2H, s, benzyllic H-0, 0').

1,1'-(methylenebis(4,1-phenylene))bis(3-(2-chlorobenzyl)urea) (10g): White solid, yield: 95%, mp: 257.3 °C; IR (cm⁻¹): 3307 (N-H str), 3031 (Ar C-H str), 2917 (Ali. CH₂ C-H str), 1631 (C=O str),
N,N'-(methylenebis(4,1-phenylene))bis(morpholine-4-carboxamide) (16H, m, Ar-H-13, 13', 3, 5', 5, 15', 15, 14, 14', 16, 16', 2, 6, 2', 6'), 6.62 (2H, t, J = 5.6 Hz, N-H-9, 9'), 4.36 (4H, d, J = 6.0 Hz, H-10, 10'), 3.76 (2H, s, benzylic H-0, 0'); 13C NMR (100 MHz, DMSO-d6) δ: 155.1 (C-8, C8'), 138.1 (C-11, C-11'), 137.3 (C-4, C-4'), 134.4 (C-12, C-12'), 131.9 (C-2, C-2', C-6, C-6'), 129.0 (C-13, C13'), 128.8 (C-16, C-16'), 128.7 (C-14, C-14'), 128.5 (C-1, C-1'), 127.1 (C-15, C-15'), 117.8 (C-3, C-3', C-5, C-5'), 40.7 (benzylic C-0, C-0'), 40.1 (C-10, C-10').

N,N'-methylenebis(4,1-phenylene)bis(piperydine-1-carboxamide) (10i): Pale yellow solid, yield: 99%, mp: 202.5 °C; IR (cm⁻¹): 3317 (N-H str), 3037 (Ar C-H str), 1637 (C=O str), 1590 (C=C str), 1516 (aromatic ring str), 1412 (C-H bend), 1301, 1236 (C-N str), 805 (C-H str); 1H NMR (400 MHz, CDCl₃) δ: 8.33 (2H, s, N-H-7, 7'), 7.34-7.01 (4H, dd, J = 7.6 Hz, Ar-H-3, 3', 5, 5', 2, 2', 6, 6'), 3.77 (2H, s, benzylic H-0, 0'), 3.76 (2H, s, H-10, 10'), 1.95-1.90 (8H, m, H-11, 11, 11', 13, 13, 13', 13').

N,N'-methylenebis(4,1-phenylene)bis(4-methylpiperazine-1-carboxamide) (10k): White solid, yield: 99%, mp: 201.5 °C; IR (cm⁻¹): 3334 (N-H str), 3037 (Ar C-H str), 1640 (C=O str), 1520 (aromatic ring str), 1417 (C-H bend), 1302, 1245 (C-N str), 1113 (ring C-O-C str), 805 (C-H str); 1H NMR (400 MHz, CDCl₃) δ: 8.45 (2H, s, N-H-7, 7'), 7.35-7.04 (8H, dd, J = 8.4 Hz, J = 8.4 Hz, Ar-H-3, 5, 3', 5', 2, 2', 6, 6'), 3.77 (2H, s, benzylic H-0, 0''), 3.59 (8H, t, J = 4.4 Hz, 10, 10', 14, 14', 10, 10', 14, 14'), 3.40 (8H, t, J = 5.2 Hz, H-11, 11, 13, 13', 11', 13', 13', 13').

N,N'-methylenebis(4,1-phenylene)bis(4-pyridine-2-yl)piperazine-1-carboxamide (10l): White solid, yield: 97%, mp: 213.8 °C; IR (cm⁻¹): 3336 (N-H str), 3041 (Ar C-H str), 2848 (ring CH₂ (near N) C-H str), 1648 (C=O str), 1596 (C-N str), 1531, 1486 (aromatic ring str), 808 (C-H str); 1H NMR (400 MHz, CDCl₃) δ: 8.62 (2H, s, N-H-7, 7'), 7.55-7.23 (8H, dd, J = 8.0 Hz, J = 8.0 Hz, Ar-H-3, 5, 3', 5', 2, 2', 6, 6'), 3.97 (2H, s, benzylic H-0, 0''), 2.70 (8H, s, 10, 10, 14, 14, 10', 14', 14'), 2.49 (8H, s, H-11, 11, 13, 13, 11', 11', 13', 13').

N,N'-methylenebis(4,1-phenylene)bis(4-pyridine-2-yl)piperazine-1-carboxamide (10m): White solid, yield: 97%, mp: 219.4 °C; IR (cm⁻¹): 3321 (N-H str), 3032 (Ar C-H str), 2892 (aliph. CH str), 2856 (ring CH₂ C-H str), 1637 (C=O str), 1416 (aromatic ring str), 1416 (C-H bend), 1301, 1246 (C-N str), 802 (C-H str); 1H NMR (400 MHz, CDCl₃) δ: 8.62 (2H, s, N-H-7, 7'), 8.13 (2H, d, J = 4.0 Hz, Ar-H-17, 17'), 7.56 (2H, t, J = 7.6 Hz, Ar-H-19, 19'), 7.38-7.05 (8H, dd, J = 8.4 Hz, J = 8.4 Hz, Ar-H-3, 5, 3', 5', 2, 2', 6, 6'), 6.86 (2H, d, J = 8.4 Hz, Ar-H-20, 20'), 6.67 (2H, t, J = 5.6 Hz, Ar-H-18, 18'), 3.78 (2H, s, benzylic H-0, 0'), 3.58 (16H, s, H-10, 10', 10', 10, 11, 11, 11', 13, 13, 13', 13', 14, 14, 14', 14').
Benzene C-H wag); \(^1\)H NMR (400 MHz, CDCl\(_3\)) \(\delta\): 7.29-7.05 (8H, dd, J = 8.4 Hz, J = 8.0 Hz, Ar-H-3, 5, 3', 5', 2, 2', 6, 6'), 6.27 (2H, s, N-H-7, 7'), 3.86 (2H, s, benzylic H-0, 0'), 1.76 (16H, m, H-11, 11, 12, 12, 13, 13, 14, 14, 11', 11', 12', 12', 13', 13', 14', 14'); \(^1\)C NMR (100 MHz, CDCl\(_3\)) \(\delta\): 155.3 (C-8, C-8'), 137.4 (C-4, C-4'), 135.9 (C-2, C-2', C-6, C-6'), 129.3 (C-1, C-1'), 120.1 (C-3, C-3', C-5, C-5'), 46.7 (C-10, C-10', C-15, C-15'), 40.6 (benzylic C-0, C-0'), 28.7 (C-11, C-11', C-14, C-14'), 27.3 (C-12, C-12', C-13, C-13').

LCMS m/z (%): 450 (M+D\(^+\)) (100 %); Anal. Calcd for C\(_{27}\)H\(_{36}\)N\(_4\)O\(_2\): C, 72.29; H, 8.09; N, 12.49; O, 7.13%. Found: C, 72.15; H, 8.16; N, 12.41; O, 7.28%.

2.4. Antibacterial Activity

Primary antimicrobial screening study by whole cell growth inhibition assay method, using the title compounds at a single concentration, in duplicate (n=2) was done. The inhibition of growth is measured against five bacterial species and two fungi by Community for Open Antimicrobial Drug Discovery (CO-ADD), a global open-access screening initiative of The University of Queensland’s Institute for Molecular Bioscience which is funded by the Wellcome Trust and The University of Queensland, Australia to uncover significant and rich chemical diversity held outside of corporate screening collections and provides unencumbered free antimicrobial screening for any interested academic researcher. CO-Add has been recognized as a novel approach in the fight of superbugs.

2.4.1. Sample Preparation

Samples were provided by the collaborator and stored frozen at -20 °C. Samples were prepared in DMSO and water to a final testing concentration of 32 \(\mu\)g/mL, in 384-well, non-binding surface plate (NBS) for each bacterial/fungal strain, and in duplicate (n=2), and keeping the final DMSO concentration to a maximum of 1% DMSO. All the sample-preparation was done using liquid handling robots. Compounds that showed solubility issues during stock solution preparation are detailed in the data sheet.

2.4.2. Antimicrobial Assay Procedure

All bacteria were cultured in Cation-adjusted Mueller Hinton broth (CAMHB) at 37 °C overnight. Then a sample of each culture was diluted 40-fold in fresh broth and incubated at 37 °C for 1.5-3.0 h. The resultant mid-log phase cultures were diluted (CFU/mL measured by OD\(_{600}\)), then added to each well of the compound containing plates, giving a cell density of 5x10\(^5\) CFU/mL and a total volume of 50 \(\mu\)L. All the plates were covered and incubated at 37 °C for 18 h without shaking.

2.4.3. Antifungal Assay Procedure

Fungi strains were cultured for three days on Yeast Extract-Peptone Dextrose (YPD) agar at 30 °C. A yeast suspension of 1x10\(^6\) to 5x10\(^6\) CFU/mL (as determined by OD\(_{350}\)) was prepared from five colonies. The suspension was subsequently diluted and added to each well of the compound containing plates giving a final cell density of fungi suspension of 2.5x10\(^3\) CFU/mL and a total volume of 50 \(\mu\)L. All plates were covered and incubated at 35 °C for 24 h without shaking.

2.4.4. Antibiotic Standards Preparation and Quality Control

Colistin and vancomycin were used as positive bacterial inhibitor standards for Gram-negative and Gram-positive bacteria, respectively. Fluconazole was used as a positive fungal inhibitor standard. The antibiotics were provided in 4 concentrations, with two above and two below its MIC value and plated in to the first 8 wells of column 23 of the 384-well NBS plates. The quality control (QC) of the assays was determined by the antimicrobial controls and the Z'-factor (using positive and negative controls). The tested strains and positive controls are listed in supporting information. All antibiotic and antifungal controls displayed inhibitory values within the expected range. For inhibitory results for controls please contact the CO-ADD at support@co-add.org.
2.5. Antioxidant Activity

The beneficial effects of fruits, vegetables, beverages and newly synthesized drug molecules on human health have been attributed to their antioxidant activities. Therefore, antioxidant activity of food products is recognized as one of the important parameters in determining their functional values. Until now, antioxidant activity has been measured by various chemical and biological methods; 1. β-Carotene Bleaching (BCB) Test 2. Thiobarbituric Acid Reactive Species (TBARS) Assay 3. DPPH (1,1-diphenyl-2-picrylhydrazyl) Radical Scavenging Assay 4. FRAP (The ferric reducing antioxidant Power) assay and 5. Phycocerythrin Assay. The present study employed DPPH Radical Scavenging Assay to assess the antioxidant activity of the title compounds. 36

2.5.1. Antioxidant Activity by DPPH Scavenging Assay

Antioxidant potential of the chemicals was estimated using modified DPPH free radical scavenging assay in 96 micro-well flat plates (Tepe et al., 2005; Maya et al., 2014). Stock solutions of the chemicals were prepared as 1 mg/mL in DMSO. Each well was filled in with 200 μL chemical in DMSO starting from 100 μg/mL down to the lowest 20 μg/mL. Then 5μL of the DPPH solution (2.5 mg/mL in methanol) was added to each well. After keeping the plate in the darkness for 30 minutes, the optical density (OD) of each well was read using Tecan Infinite M200 micro plate reader at wavelength 517 nm. All the tests were performed in triplicate (n=3). All the values are reported in Mean ± SD. Percentage of inhibition was calculated using the formula:

\[
\text{%Inhibition} = \frac{\text{OD (DPPH) - Sample} \times 100}{\text{OD (DPPH)}}
\]

The radical scavenging activity was examined and compared with other natural antioxidant, ascorbic acid which was used as positive control. Table 2 explains the % inhibition of DPPH at different concentrations.

2.6. Molecular Docking Studies

The DNA gyrase is an important bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. Gyrase belongs to a class of enzymes known as topoisomerases which are involved in the control of topological transitions of DNA. From an enzymological stand point it is of inherent interest how gyrase influences the topological state of DNA molecules. In addition, more studies were focused on DNA gyrase as the intracellular target of a number of antibacterial agents and as a paradigm for other DNA topoisomerases (Ter et al., 2001). 37

Streptomycin, an antibiotic derived from Streptomyces griseus, irreversibly binds to the 16S rRNA and S12 protein within the bacterial 30S ribosomal subunit. Consequently this reagent interferes with the assembly of initiation complex between mRNA and the bacterial ribosome, thereby inhibiting the initiation of protein synthesis. In addition, streptomycin induces misreading of the mRNA template and causes translational frame shift and results in premature termination which ultimately leads to bacterial cell death (Petersen et al., 2004). 38

2.6.1. Materials and Methods: Accession of Target Protein

The three-dimensional structure of DNA gyrase A (PDB: 3LPX) and the reference drugs such as Streptomycin (Pub Chem ID 19649) was downloaded from the RCSB protein Data Bank. The atomic coordinates of the protein was estranged and geometry optimization was done using Argus Lab 4.0.1. The enzyme 3LPX and the reference drug, Streptomycin (Pub Chem ID 19649) were shown in Figure 2 (A&B). 39
2.6.2. Ligand Preparation

The chemical structures of the compounds were drawn using ChemBioDraw and converted all the ligands into Pdbqt file format and atomic coordinates were generated using Pyrx 2010.12.

2.6.3. Analysis of Target Active Binding Sites

The active sites are the coordinates of the ligand in the original target protein grids, and these active binding sites of target protein were analyzed using the Drug Discovery Studio version 3.0 and 3D Ligand Site virtual tools.

2.6.4. Molecular Docking Analysis

Molecular docking studies were carried against DNA gyrase A protein with the title compounds, 10a-m and the reference drug, streptomycin using the docking module implemented in Pyrx 2010.12. Initially the protein structures were protonated with the addition of polar hydrogens, followed by energy minimization with the MMFF94x force field, in order to get the stable conformer of the proteins. Flexible docking was employed, the inhibitor binding site residues were and highlighted through the “site finder” module implemented in the Pymol software. The grid dimensions were predicted as X: 28.27, Y: 27.13, Z: 28.51 for Aromatase respectively. The docking was carried out with the default parameters i.e., placement: triangle matcher, recording 1: London dG, refinement force field and a maximum of 10 conformations of each compound were allowed to be saved in a separate data base file in a mdb format. After the docking process, the binding energy and binding affinity of the protein ligand complexes were calculated using Pymol viewer tool (www.pymol.org).

2.6.5. Structural Analysis and Visualization

Protein and ligand interactions were analysed and visualized through Pymol viewer tool (www.pymol.org).

Figure 2. A. DNA Gyrase A (E. coli) B. Streptomycin-PC ID 19649
3. Results and Discussion

3.1. Chemistry

A new series of bisurea derivatives of 4,4'-methylenebis(phenyl isocyanate) were synthesized by simple nucleophilic substitution using different acyclic and alicyclic amines one after another which were added drop wise at 10-15 °C in the presence of a base, TEA in THF and later at 45-50 °C with constant stirring for 1 h as depicted in Scheme 1. The resulting insoluble bisurea derivatives 10a-m were filtered off and further purified by washing with methanol.

The structures of the title compounds were established by FT-IR, $^1$H, $^{13}$C NMR, mass spectra and elemental analysis. In IR spectra, stretching bands at 3482-3314 cm$^{-1}$, 3336-3302 cm$^{-1}$, 3076-3004 cm$^{-1}$, 2960-2906 cm$^{-1}$ and 2866-2848 cm$^{-1}$ belong to O-H, N-H, aromatic C-H, aliphatic C-H and C-H of ring CH$_2$ stretching respectively. Absorption bands at 1648-1620 cm$^{-1}$ represent C=O stretching of bisurea derivatives. The wave numbers at 1307-1289 and 1246-1214 cm$^{-1}$ correspond to C-N stretching and 1057-1026 cm$^{-1}$ correspond to C-O stretching. In $^1$H NMR spectra of the bisurea derivatives, O-H proton resonated at 5.42-3.92 ppm. N-H proton signal appeared at 9.27-8.33 and 6.99-6.08 ppm. The aromatic protons of phenyl, pyridinyl, thiophenyl, fluorobenzyl and chlorobenzyl rings appeared at 8.53-6.67 ppm. The methylene protons of pyrrolidine, piperidine, morpholine, piperazine, azepane moieties appeared at 3.75-1.76 ppm. Aliphatic methyl(ene) protons resonated in the region 4.46-0.87 ppm. The carbonyl carbon (C-8, 8') of the urea moiety resonated in the region 155.6-154.9 ppm and that of methylenic carbon (C-0, 0') common to the two phenyl groups resonated between 41.9-40.1 ppm. The LCMS and CHN analysis data obtained for 10a and 10m were in good agreement with the calculated values, and thus provided the additional support for the title compounds.

3.2. Antimicrobial Activity

Table 1. Antimicrobial activity with % inhibition of the title compounds 10a-m

| Compound Code | Sa    | Ec    | Kp    | Pa    | Ab    | Ca    | Cn    | Conc. |
|---------------|-------|-------|-------|-------|-------|-------|-------|-------|
| 10a           | 39.27 | -3.35 | 19.41 | 21.49 | 0.04  | 12.27 | -56.75| 32 ug/mL |
| 10b           | 39.25 | 2.92  | 1.09  | 24.99 | 4.87  | 2.27  | -57.49| 32 ug/mL |
| 10c           | 27.37 | 1.53  | 11.19 | 20.89 | 0.62  | -0.17 | -38.07| 32 ug/mL |
| 10d           | 38.55 | -5.58 | 5.00  | 23.05 | -3.62 | 6.29  | -66.42| 32 ug/mL |
| 10e           | 43.02 | 3.89  | 18.06 | 24.80 | 11.12 | 3.50  | 7.56  | 32 ug/mL |
| 10f           | 46.23 | 4.52  | 20.19 | 24.92 | 14.31 | 4.25  | 9.30  | 32 ug/mL |
| 10g           | 44.01 | 4.02  | 19.46 | 24.10 | 12.76 | 4.59  | 8.24  | 32 ug/mL |
| 10h           | 30.22 | 0.09  | 16.99 | 24.43 | 5.12  | -2.82 | -36.92| 32 ug/mL |
| 10i           | 21.66 | -3.07 | 6.07  | 19.72 | -3.13 | 19.82 | 2.44  | 32 ug/mL |
| 10j           | 29.19 | 1.12  | 19.30 | 17.98 | 12.02 | 2.61  | 10.23 | 32 ug/mL |
| 10k           | 42.05 | 3.67  | 18.91 | 19.47 | 17.22 | 2.71  | 6.67  | 32 ug/mL |
| 10l           | 51.83 | 5.16  | 22.24 | 23.73 | 21.84 | 24.16 | 9.24  | 32 ug/mL |
| 10m           | 48.46 | 4.68  | 20.20 | 25.74 | 18.03 | 14.16 | 9.32  | 32 ug/mL |

**Sa**: Staphylococcus aureus; **Ec**: Escherichia coli; **Kp**: Klebsiella pneumonia; **Pa**: Pseudomonas aeruginosa; **Ab**: Acinetobacter baumannii; **Ca**: Candida albicans; **Cn**: Cryptococcus neoformans; **Conc**: Concentration
The in vitro primary antimicrobial inhibition of growth screening was studied against 5 bacteria and 2 fungi by whole cell growth inhibition assays, using the title compounds at a single concentration, in duplicate (n=2). All the title compounds showed moderate antimicrobial activity against the selected resistant pathogens at a concentration of 32.0 µg/µL (Table 1).

3.3. Antioxidant Activity

All the title compounds showed moderate antioxidant activity by DPPH method. Among the title compounds 10h and 10m showed the highest and 10e and 10d exhibited noteworthy antioxidant activity (Table 2).

| Compound Code | % of inhibition of DPPH [Mean ± SD] at different concentrations (µg/mL) |
|---------------|---------------------------------------------------------------------|
|               | 20                    | 40          | 60          | 80          | 100         |
| 10a           | 31.17±1.12             | 33.99±1.12  | 38.72±0.53  | 39.86±0.48  | 47.33±0.07  |
| 10b           | 31.02±0.60             | 31.25±0.57  | 32.55±0.49  | 33.16±0.47  | 33.31±0.36  |
| 10c           | 29.19±0.30             | 36.66±1.16  | 39.18±0.56  | 40.07±1.00  | 43.37±1.03  |
| 10d           | 30.11±0.57             | 38.72±1.09  | 41.31±0.44  | 42.76±0.51  | 43.60±0.64  |
| 10e           | 30.26±0.48             | 35.29±0.64  | 37.73±1.05  | 42.30±1.01  | 57.55±0.82  |
| 10f           | 30.34±0.89             | 31.71±0.45  | 33.38±0.64  | 35.59±0.22  | 40.63±0.49  |
| 10g           | 28.96±0.42             | 35.44±0.73  | 36.97±1.22  | 37.04±0.45  | 38.57±1.25  |
| 10h           | 31.48±1.40             | 37.27±0.57  | 43.90±0.38  | 45.58±1.34  | 55.34±0.46  |
| 10i           | 31.10±1.30             | 32.70±0.43  | 38.34±0.54  | 39.79±0.83  | 45.58±1.16  |
| 10j           | 30.56±1.04             | 33.54±1.17  | 36.28±0.92  | 40.32±1.12  | 42.91±0.48  |
| 10k           | 31.55±0.59             | 35.14±1.02  | 41.46±0.87  | 42.00±0.90  | 43.07±0.17  |
| 10l           | 27.82±0.80             | 30.41±0.65  | 37.58±0.85  | 40.78±0.63  | 46.80±0.82  |
| 10m           | 35.90±1.09             | 37.73±0.75  | 42.76±0.24  | 47.79±0.66  | 52.74±0.80  |
| Standard (Ascorbic acid) | 85.82±1.40 | 87.2±0.94 | 89.1±0.94 | 89.25±0.32 | 89.25±0.32 |

*All the values are reported in Mean + SD (n=3).

3.4. Molecular Docking Studies

In order to provide strength to the synthesized compounds, docking analysis was carried out for compounds 10a-m with selective pharmacological target such as DNA Gyrase A, protein of E. coli which is a suitable target for anti-bacterial activity. The crystal structure of DNA Gyrase A (PDB id: 3LPX) was retrieved from the protein data bank and the reference drug Streptomycin (PC ID 19649) from PubChem DrugBank. The docking results of DNA Gyrase A showed that the compounds, 10a-m have significant binding modes when compared with the control drug, Streptomycin (-6.9 kcal/mol). Among the 13 compounds, 10l, 10f, 10m, 10g, 10e and 10k showed highest binding affinity towards DNA Gyrase A. The H-bonds, binding affinities and energy profiles of compounds 10a-m along with reference drug towards the active site amino acids of the enzyme are summarized in Table 3.
New symmetrical acyclic and alicyclic bisurea derivatives

Table 3. Bonding characterization of title compounds 10a-m

| Compound Code | Rank | Bond energy (kcal/mol) | Binding interaction | Bond Length (Å) | Bond Angle (°) | Bond Type |
|---------------|------|------------------------|---------------------|-----------------|----------------|-----------|
| 10a           | 12   | -7.1                   | Lys270 HZ…OC        | 1.9             | 110.3          | H-acc     |
|               |      |                        | Lys 270 HZ…OC       | 2.0             | 109.6          | H-acc     |
|               |      |                        | Asp 297 CA…HN       | 1.8             | 122.2          | H-don     |
|               |      |                        | Gly 110 OC…HN       | 1.9             | 121.7          | H-don     |
|               |      |                        | Gly 110 OC…HN       | 2.3             | 123.1          | H-don     |
| 10b           | 13   | -7.0                   | Asn 108 CG…HO       | 2.3             | 121.5          | H-don     |
|               |      |                        | Phe 109 CA…OC       | 2.0             | 115.1          | H-acc     |
|               |      |                        | Gly 110 HN…OC       | 2.8             | 124.4          | H-acc     |
|               |      |                        | Thr 219 CA…HO       | 2.0             | 119.9          | H-don     |
|               |      |                        | Leu 264 HN…OC       | 2.2             | 114.7          | H-acc     |
| 10c           | 11   | -7.4                   | Val 103 OC…HO       | 2.0             | 124.6          | H-don     |
|               |      |                        | Gly 105 HN…OC       | 2.2             | 124.7          | H-acc     |
|               |      |                        | Gly 105 OC…HN       | 2.2             | 124.2          | H-don     |
| 10d           | 10   | -8.0                   | Asp 104 CG…HN       | 2.4             | 118.7          | H-don     |
|               |      |                        | Glu 263 CD…NH       | 2.6             | 116.7          | H-acc     |
|               |      |                        | Gly 105 OC…NH       | 2.3             | 121.8          | H-acc     |
| 10e           | 5    | -8.8                   | Gly 110 OC…HN       | 1.9             | 123.1          | H-don     |
|               |      |                        | Gly 110 OC…HN       | 2.4             | 121.7          | H-don     |
| 10f           | 2    | -9.0                   | Gly 105 CA…HN       | 2.3             | 124.2          | H-don     |
| 10g           | 4    | -8.8                   | Gly 110 OC…HN       | 2.0             | 123.1          | H-don     |
| 10h           | 9    | -8.4                   | Gly 110 CA…HN       | 2.3             | 121.7          | H-don     |
| 10i           | 8    | -8.4                   | Gly 105 OC…HN       | 2.4             | 121.3          | H-don     |
| 10j           | 7    | -8.5                   | Gly 110 HN…OC       | 2.1             | 122.2          | H-acc     |
| 10k           | 6    | -8.7                   | Asp 297 OC…HN       | 2.6             | 121.4          | H-don     |
| 10l           | 1    | -9.7                   | Asp 270 NZ…OC       | 2.6             | 110.3          | H-acc     |
| 10m           | 3    | -9.0                   | Asp 297 CA…HN       | 2.0             | 122.4          | H-don     |
| *STM          | R    | -6.9                   | Arg 139 CG…HN       | 2.2             | 124.4          | H-don     |
|               |      |                        | Leu 135 CD…HN       | 2.7             | 125.7          | H-acc     |
|               |      |                        | His 132 CB…OH       | 2.5             | 125.0          | H-acc     |
|               |      |                        | Asp 35 OC…OC        | 3.4             | 116.7          | H-acc     |
|               |      |                        | Asp 53 OC…OC        | 2.9             | 118.9          | H-acc     |
|               |      |                        | Asp 58 OD…OH        | 2.0             | 118.6          | H-acc     |
|               |      |                        | Asp 58 OD…HN        | 2.5             | 116.4          | H-don     |
|               |      |                        | His 132 ND…OC       | 2.8             | 126.2          | H-acc     |
|               |      |                        | His 132 ND…OC       | 2.7             | 120.0          | H-acc     |
|               |      |                        | His 132 OC…OH       | 2.5             | 119.8          | H-acc     |

*Streptomycin (STM), the reference drug against *E. coli* DNA Gyrase A protein

The binding modes of compounds 10l, 10f, 10m, 10g, 10e and 10k (Figure 3) suggested that they fitted more stably in to the DNA Gyrase A binding site (active site). Hence the present
investigation demonstrated that the synthesized compounds would be the promising next generation anti-microbial drugs, which could be effectively used in the treatment of microbial infections.

4. Conclusion

In conclusion, the fabricated title compounds were synthesized in a simple method with ease in high yields and evaluated their antibacterial activity. The in vitro combating potentialities of the title compounds against 5 bacterial and 2 fungal pathogens and their antioxidant activity revealed that all the title compounds were moderate antimicrobials and moderate antioxidants. However, the binding modes and binding energies of the compounds 10e, 10f, 10g, 10k, 10l and 10m in molecular docking
New symmetrical acyclic and alicyclic bisurea derivatives

studies, surprisingly suggested that they could be the promising next generation antimicrobials for treating infectious diseases.

Conflict of Interest

The authors confirm that this article content has no conflict of interest.

Acknowledgements

P. Hari Babu expresses his thanks to Prof. C. Suresh Reddy, S. V. University, Tirupathi for providing EZ-melt Automated Melting Point Apparatus and FT-IR facility, Dr. G. Ananda Reddy, Principal, P.V.K.N. Government College, Chittoor and Dr. T. Balasubrahmanya Reddy, Asso. Prof. of Physics, Government Degree College, Puttur, Chittoor Dist, Andhra Pradesh, India. He also expresses his immense gratitude to CO-ADD as Antimicrobial screening was performed by CO-ADD (The Community for Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK) and the University of Queensland, Australia.

Supporting Information

Full experimental details, FTIR, 1H, 13C NMR and Mass spectra; CHN analysis of 10a and 10m; antimicrobial screening and antioxidant activity evaluation with references; tables and figures are furnished in Supplementary Information which accompanies this paper on http://www.acgpubs.org/OC.

ORCID
Chamarthi Naga Raju: 0000-0001-6566-2118
Ponne Venkata Chalapathi: 0000-0001-5775-2439
Pulluru Hari Babu: 0000-0002-0078-3127
Dasari Balija Janakiram: 0000-0003-3115-2931
Gutala Sindhu Reddy: 0000-0001-7469-6512
Kallimakula Venkatareddy Saritha: 0000-0003-1597-8346
Chintha Venkataramaiah: 0000-0002-0493-6047
Wudayagiri Rajendra: 0000-0002-7974-7945

References
[1] Keiji Fukuda. Antimicrobial Resistance: Global Report on Surveillance 2014. 2014.
[2] Christopher, T.W.; Timothy, A.W. Prospects for new antibiotics: a molecule-centered perspective. J. Antibi. 2014, 67, 7-22.
[3] Liao-Bin, D.; Jeffrey, D.R.; Ben, S. Antibacterial sulfur-containing platensimycin and platencin congeners from Streptomyces platensis SB12029. Bioorg. Med. Chem. 2016, 24, 6348-6353.
[4] Sheo B. S. Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase. Bioorg. Med. Chem. 2016, 24, 6291-6297.
[5] Lyn P.N.D. Lead toxicity. A review of the literature. Part I: Exposure, evaluation and treatment. Alternat. Med. Rev. 2006, 11, 1, 2-22.
[6] Ronald, L.P.; Xianli, W.; Karen, S. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J. Agric. Food Chem. 2005, 53, 4290-4302.
[7] Lyn P.N.D. Lead toxicity part II: The role of free radical damage and the use of antioxidants in the pathology and treatment of lead toxicity. Alternat. Med. Rev. 2006, 11, 2, 114-127.
[8] a)Thomas, C.G.; George, S. A critical appraisal of the evolution of N-Nitrosoureas as anticancer drugs. Chem. Rev. 1997, 97, 829 -1013; b) Zijian, L.; Yu, W.; Huafang, L.; Dazhuang, Z.; Lihui, W.; Yanfang, Z.; Ping, G. Design, synthesis and biological evaluation of novel thieno[3,2-d] pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents. Eur. J. Med. Chem. 2014, 85, 215-227.
[9] a)Yu, Z.; Jiang, W.; Zhanni, G.; Shuni, W.; Wei, Z.; José, L.A.; Vadim, A.S.; Kunisuke, I.; Hong, L. Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: New structural trends and therapeutic areas. Chem. Rev. 2016, 116, 422-518; b) Xiaobing, C.; Bojian, X.; Liang, C.; Feng, Z.; Beibei, C.; Huifang, L.; Xingxing, F.; Lili, H.;
potent H+/K+-ATPase inhibitors. [benzo[d]isothiazol-3-yl) piperazin-1-yl]-1,5-dioxo pentan-2-ylcar-bamate urea/thiourea derivatives as antimicrobial activity.

Synthesis of some pyridazine derivatives carrying urea, thiourea and sulfonamide moieties and their antihyperglycaemic agents. 

Regorafenib: Analternative mechanism for anti-color ectal cancer chemotherapy?

Possessing Pyrrolo[3,2-c]Pyridine Scaffold.

An alternative mechanism for anti-color ectal cancer chemotherapy?

Chem. Soc.

Antibacterial activity in

Design, synthesis, and antiproliferative activity against melanoma cell line.

M.M.; El-Gamal, M.I.; Abdel-Maksoud, M.S.; Yoo, K.H.; Oh, C-H. Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives.

2011, 55, 796-799.

Chem. Pharm. Bull.

5.22.02,6)undec-8-ene-3,5-dione. Chem. Pharm. Bull. 2007, 55, 796-799.

Chinnasamy, R.P.; Sundararajan, R. Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholinoph/piperidino methyl)-2,3-dioxoindo-lin-5-yl)urea derivatives. Eur. J. Med. Chem. 2011, 46, 6057-6065.

William, C.D.; Rupesh, N.; Mekala, G.; Monica, B.; Gary, N.P.; Anthony, P.R.; David, W.W.; Stephen, N. Rational design of substituted diarylureas: A scaffold for binding to G-quadruplex motifs. J. Med. Chem. 2008, 51, 7751-7767.

Kitti, A.; Apilak, W.; Virapong, P. Facile synthesis of N-Aroylurea analogs as potential antioxidants. Eur. J. Sci. Res. 2009, 31, 510-518.

Hassan, M.F.; Khalid, A.K.; Abdullah, M.A. Synthesis and biological evaluation of new 3-trifluoromethylpyrazolesulfonfyl-urea and thiourea derivatives as antibacterial and antimicrobial agents. J. Fluorine Chem. 2011, 132, 131-137.

Shweta, V.; Riaz, H.; Neha, K. Synthesis of phenylurea derivatives & their evaluation as antihyperglycaemic agents. Indo. Global. J. Pharm. Sci. 2013, 5, 33-39.

Muhammad, A.A.; Shahid, H.; Muhammad, F.; Jörg, K.; Nasir, M. Conjugates of degraded and oxidized hydroxyethyl starch and sulfonfylurea: Synthesis, characterization and in vivo antidiabetic activity. Bioconjugate Chem. 2015, 26, 120-127.

a) Rajesh, H.T.; Atish, H.R.; Girish, D.H.; Ashish, P.K. The novel 3,4-dihydropyrimidin-2(1H)-one urea derivatives of N-aryl urea: Synthesis, anti-inflammatory, antibacterial and antifungal activity evaluation. Bioorg. Med. Chem. Lett. 2011, 21, 4648-4651; b) Keche, A.P.; Kamble, V.M.. Synthesis and anti-inflammatory and antimicrobial activities of some novel 2-methylquinazolin-4(3H)-one derivatives bearing urea, thiourea and sulphonamide functionalities. Arab. J. Chem. 2014, doi: http://dx.doi.org/10.1016/j.arabjc.2014.10.025.

Anamika Sharma; Suhas, R.; Chandana, K.V.; Syeda, H.B.; Channe, G.D. tert-Butyl 1,5-bis(4-benzo[d]isothiazol-3-yl) piperazine-1-yl)-1,5-dioxopentan-2-ylcar-bamate urea/thiourea derivatives as potent H+/K+-ATPase inhibitors. Bioorg. Med. Chem. Lett. 2013, 23, 4096-4098.

a) Hee, J.K.; Hye, J.C.; Hwan, K.; Mohammed I ElGamal; Chang-Hyun Oh; So, H.L.; Taeblo, S.; Jung-Mi, H.; Kyung, H.Y. New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: Design, synthesis, and antiproliferative activity against melanoma cell line. Bioorg. Med. Chem. Lett. 2012, 22, 3269-3273. b) Eun, J.K.; Mohammed I ElGamal; Chang-Hyun Oh; So, H.L.; Taeblo, S.; Garam, K.; Hong, S.C.; Jun, H.H.; Sang-gi, L.; Kyung, H.Y. New diarylureas and diarylamides possessing 8-amino(acetamido) quinoline scaffold: Synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition and in silico studies. Eur. J. Med. Chem. 2013, 70, 10-21.

a) Mohammad, A.K.; Mohammed I ElGamal; Mohammed S Abdel-Maksoud; Mahmoud M Gamal El-Din; Yoo, K.H.; Oh, C-H. Broad-Spectrum Antiproliferative Activity of Diarylureas and Diarylamides Possessing Pyrrolo[3,2-c]Pyridine Scaffold. J. Pharm. Pharmacol. 2014, 2, 157-169; b) Gamal El-Din, M.M.; El-Gamal, M.I.; Abdel-Maksoud, M.S.; Yoo, K.H.; Oh C-H. Synthesis and broad-spectrum antiproliferative activity of diarylureas and diarylamides possessing 1,3,4-oxadiazole derivatives. Bioorg. Med. Chem. Lett. 2015, doi: http://dx.doi.org/10.1016/j.bmcl.2015.03.001.

Pavi, K.; Perkovi, I.; Cindri, M.; Pranj, M.; Martin-Kleiner, I.; Kralj, M.; Schols, D.; Hadijapavli-Litina, D.; Katsori, A-M.; Zorc, B. Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity. Eur. J. Med. Chem. 2014, 86, 502-514.

Ram Shankar, U.; Girish, M.K.; Nageswara Rao, V.; Jaya Kishore, V.; Shailesh, S.D.; Vivek S.; Jyoti, C. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of 4-Azatricyclo[5.2.2.02,6]undec-8-ene-3,5-dione. Eur. J. Med. Chem. 2015, 23, 1402-1412.

a) Figueroa, V.L.; Díaz, C.F.; Ceballos, R.G.; López, R.M.; Maldonado, V.G.; Camacho, L.A. QSAR Studies on urea and thiourea derivatives. Relationship between descriptors Log p, π, MR and MV and Antibacterial activity in Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli. J. Arg. Chem. Soc. 2008, 96, N° (1-2), 87-100; b) Dogruer, S.D.; Uru, S.; Onkol, T.; Ozcelik, B.; Sahin, F.M. Synthesis of some pyridazine derivatives carrying urea, thiourea and sulfonamide moieties and their antimicrobial activity. Turk J. Chem. 2010, 34, 57-65; c) Zi-Lin, L.; Qing-Shan, L.; Hong-Jia, Z.; Yang, H.; Di-Di, Z.; Hai-Liang, Z. Design, synthesis and biological evaluation of urea derivatives from o-
hydroybenzyl-amines and phenylisocyanate as potential FabH inhibitors. *Bioorg. Med. Chem.* **2011**, *19*, 4413–4420; d) Madhava, G.; Venkata Subbaiah, K.; Sreenivasulu, R.; Naga Raju, C. Synthesis of novel urea and thiourea derivatives of diphenylphosphoramidate and their antimicrobial activity. *Pharm. Lett.* **2012**, *4*, 1194-1201; e) Liao-Bin, D.; Jeffrey, D.R.; Li, L.; Claudia, R.; Michael, D.C.; Ben, S. In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycins. *Bioorg. Med. Chem.* **2017**, *25*, 1990-1996.

[24] a) Suhas, R.; Chandrashekhar, S.; Channe Gowda, D. Synthesis of uriedo and thiourido derivatives of peptide conjugated heterocycles – A new class of promising antimicrobials. *Eur. J. Med. Chem.* **2012**, *48*, 179-191; b) Mahendranath, M.; Madhava Chetty, K. Synthesis, Spectral characterization and Antibacterial activity of Novel thioureia analogues. *Int. J. Curr. Microbiol. App. Sci.* **2015**, *4*, 900-909; c) Xue-Jie, F.; Jeyakkumar, P.; Srinivasa Rao, A.; Qian, Z.; Cheng-He, Z. Design, synthesis and biological evaluation of 5-fluorouracil-derived benzimidazoles as novel type of potential antimicrobial agents. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 2584-2588.

[25] Yi-Jun, W.; Yun-Kai, Z.; Guan-Nan, Z.; Weilem, B.A.R.; Meng-Ning, W.; Pranav, G.; Xiao-Yu, Z.; Suneet, S.; Suresh, V.A.; Amal, K.; Zhi, S.; Zhe-Sheng, C. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. *Cancer Lett.* **2017**, *396*, 145-154.

[26] Shaveta, S.M.; Palwinder, S. Hybrid molecules: The privileged scaffolds for various pharmaceuticals. *Eur. J. Med. Chem.* **2016**, *110*, 544-550.

[27] Ramnarayan, S.R.; Rajan, H.N.; Sergei, V.G.; Betty, Yu.; John, W.E. Symmetry-based HIV protease inhibitors containing a hydroxyl bis-urea isostere. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 2343-2346.

[28] Marijana, R.S.; Manka, S.; Glavas-Obrovac, L.; Piantanida, I. Permanent positive charge strongly influences DNA/RNA binding and antiproliferative activity of urea-phenanthridinium conjugates. *Eur. J. Med. Chem.* **2010**, *45*, 3281-3292.

[29] Alan, R.K.; Adel, S.G.; Svetsolav, S.; Srinivasa, R.T.; Stoyanova-Slavova, I. QSAR modeling, synthesis and bioassay of diverse leukemia RPMI-8226 cell line active agents. *Eur. J. Med. Chem.* **2010**, *45*, 5183-5199.

[30] Nadeem, S.; Alam, M.S.; James, P.S. Synthesis and anticonvulsant properties of 1-(amino-N-arylmethanethio)-3-(1-substituted benzyl-2, 3-dioxoindolin-5-yl) urea derivatives. *Eur. J. Med. Chem.* **2011**, *46*, 2236-2242.

[31] Wenhui, Z.; Yanyang, L.; Weiping, H.; Yanjin, Z.; Zhenglin, Y.; Shanyou, Y.; Shoujun, Y.; Falong, J.; Shan, Y.; Shuxin, L. Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors. *Bioorg. Med. Chem.* **2012**, *20*, 4323-4329.

[32] Gangappa, S.K.; Mahadeo, R.P.; Siddappa, A.P.; Srinivasa, B. A comprehensive review in current developments of benzothiazolebased molecules in medicinal chemistry. *Eur. J. Med. Chem.* **2015**, *89*, 207-251.

[33] Perkovic, I.; Antunovic, M.; Marijanovic, I.; Pavic, K.; Ester, K.; Kralj, M.; Vlajnic, J.; Kosalex, I.; Schols, D.; Hadjipavlou-Litina, D.; Pontiki, E.; Zorc, B. Novel urea and bis-urea primaquine derivatives with hydroxyphenyl and halogen phenyl substituents: Synthesis and biological Evaluation. *Eur. J. Med. Chem.* **2016**, *124*, 622-636.

[34] Aleksandra, P.; Dariusz, C. In search of uracil derivatives as bioactive agents - Uracils and fused uracils: Synthesis, biological activity and applications. *Eur. J. Med. Chem.* **2015**, *97*, 582-611.

[35] Nathalie, B.; Marco, W.; Mark, E.L.; Paulina, I-H.; Ricardo, P-T.; Philip, A.G.; Structure-Activity Relationships in Tripodal Transmembrane Anion Transporters: The Effect of Fluorination. *J. Am. Chem. Soc.* **2011**, *133*, 14136–14148.

[36] a) Pisochsi, A.M.; Negulescu, G.P. Methods for total antioxidant activity determination: A Review. *Biochem. Anal. Biochem.* **2011**, *1*, 106. doi: [http://dx.doi.org/10.4172/2161-1009.1000106](http://dx.doi.org/10.4172/2161-1009.1000106); b) Renda, G.; Ozgen, U.; Unal, Z.; Sabuncuoglu, S.; Palaska, E., Erdogan-Orhan, I. Flavonoid derivatives from the aerial parts of *Trifolium trifolium* M. Bieb. and their antioxidant and cytotoxicity Activity. *Rec. Nat. Prod.* **2017**, *11*(5),479-484; c) Eroz-Poyraz, I.; Akalin-Ciftci, G.; Ozturk,N. Phenolic contents, *in vitro* antioxidant and cytotoxicity activities of *Salvia aethiopis* L. and *S. ceratophylla* L. (Lamiaceae). *Rec. Nat. Prod.* **2017**, *11*(4),345-355; d) Pramod K Sahu. Design, structure activity relationship, cytotoxicity and evaluation of antioxidant activity of curcumin derivatives/analogues. *Eur. J. Med. Chem.* **2016**, *121*, 510-6.

[37] Ter, H.E.; Coll, J.T.; Austen, D.A.; Hsiao, H.M.; Swenson, L.; Jain, J. Structure of GSK3β reveals a primed phosphorylation mechanism. *Nat. Struct. Biol.* **2001**, *8*, 593-596.

[38] Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera – a visualization system for exploratory research and analysis. *J. Comput. Chem. 2004*, *25*, 1605-1612.
[39] Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* **2009**, *30*, 2785-2791.